EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AKT1 glutarylation regulated by GCDH and SIRT5 suppresses oncogenic signaling

Longchang Bai, Ruocen Liao, Yu Zhang, Yongshi Jia, Lei Shi, Hongen Xu, Liang Liang, Yu Feng, Chenfang Dong

Cell Reports · 2026

DOI: 10.1016/j.celrep.2026.117394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Longchang Bai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology (Breast Center) and Department of Pathology and Pathophysiology, Key Laboratory of Cancer Prevention and Intervention…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Sirtuins, Signal Transduction, Carcinogenesis. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant AKT1 activation is a hallmark of cancer, yet the molecular mechanisms regulating its activity remain incompletely understood. Here, we report that AKT1 undergoes glutarylation at evolutionarily conserved lysines K179 and K289. Mechanistically, AKT1 glutarylation is regulated by the metabolic enzymes GCDH and DHTKD1, which modulate glutaryl-CoA levels, and reversed by the deglutarylase SIRT5. Glutarylation at K179 disrupts the K179-E198 salt bridge and AKT1-ATP interactions, whereas K289 glutarylation perturbs ATP coordination and reduces PDK1-mediated phosphorylation, collectively inactivating AKT1. Functionally, AKT1 glutarylation inhibits cell proliferation and tumor growth, whereas GCDH promotes these oncogenic functions by suppressing glutarylation. Notably, pharmacological MYC inhibition, which downregulates GCDH and elevates AKT1 glutarylation, synergizes with the AKT inhibitor afuresertib to suppress gastric cancer cell growth, revealing a potential therapeutic vulnerability. These findings link lysine metabolism to AKT-driven cancer progression and suggest therapeutic strategies targeting glutarylation dynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktSirtuinsSignal TransductionCarcinogenesisGlutaratesHumansAnimalsCell ProliferationCell Line, TumorPhosphorylationPyruvate Dehydrogenase Acetyl-Transferring KinaseMiceLysine

Stichwörter der Autor:innen

AKT1CP: CancerCP: Molecular biologyDHTKD1GCDHSIRT5glutarylation

Substanzen

Proto-Oncogene Proteins c-aktSirtuinsSIRT5 protein, humanAKT1 protein, humanPyruvate Dehydrogenase Acetyl-Transferring KinaseLysineGlutarates

Autor:innen und Institutionen

  • Department of Surgical Oncology (Breast Center) and Department of Pathology and Pathophysiology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang Univ…
  • Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
  • Department of Biophysics, Zhejiang University School of Medicine, Hangzhou 310058, China.

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Province Natural Science Foundation

Zitieren

APA

Bai, L., Liao, R., Zhang, Y., Jia, Y., Shi, L., Xu, H., Liang, L., Feng, Y., & Dong, C. (2026). AKT1 glutarylation regulated by GCDH and SIRT5 suppresses oncogenic signaling. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117394

Vancouver

Bai L, Liao R, Zhang Y, Jia Y, Shi L, Xu H, et al. AKT1 glutarylation regulated by GCDH and SIRT5 suppresses oncogenic signaling. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117394

BibTeX
@article{Bai2026,
  author = {Bai, Longchang and Liao, Ruocen and Zhang, Yu and Jia, Yongshi and Shi, Lei and Xu, Hongen and Liang, Liang and Feng, Yu and Dong, Chenfang},
  title = {AKT1 glutarylation regulated by GCDH and SIRT5 suppresses oncogenic signaling},
  journal = {Cell Reports},
  year = {2026},
  doi = {10.1016/j.celrep.2026.117394}
}
Kostenlos starten →